Clinical Trials
272 trialsNCT02231749 2026-05-27
Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)
Bristol-Myers Squibb
Phase 3 Completed
NCT03260894 2026-05-22
Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)
Incyte Corporation
Phase 3 Completed
NCT01624220 2026-05-12
A Prospective Study Using Implanted Fiducial Markers to Assess Treatment Accuracy and Esophageal Toxicity in Spinal Stereotactic Body Radiation Therapy
M.D. Anderson Cancer Center
Phase NA Completed
NCT03945773 2026-03-13
CaboPoint
Ipsen
Phase 2 Completed
NCT03142334 2026-03-10
KEYNOTE-564
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT02853331 2026-02-02
KEYNOTE-426
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT04349267 2025-12-17
Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Completed
NCT04704219 2025-12-03
KEYNOTE-B61
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT04941768 2025-11-28
An Observational Study to Evaluate the Efficacy and Safety of Avelumab + Axitinib Combination in Participants With aRCC (AVION)
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Completed
NCT02162732 2025-11-03
Molecular-Guided Therapy for Childhood Cancer
Milton S. Hershey Medical Center
Phase NA Completed
NCT01120249 2025-09-16
S0931
SWOG Cancer Research Network
Phase 3 Completed
NCT02923349 2025-08-24
A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors
Incyte Corporation
Phase 1/2 Completed
NCT03126110 2025-08-14
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Phase 1/2 Completed
NCT02903914 2025-08-05
Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
Incyte Corporation
Phase 1 Completed
NCT02684006 2025-07-30
JAVELIN Renal 101
Pfizer
Phase 3 Completed
NCT04508725 2025-07-25
Serial Ultrasound in Metastatic Renal Cell Carcinoma (mRCC)
Stanford University
Phase NA Completed
NCT04627064 2025-07-25
ABEMA Alone or in COMBO With MK-6482
Dana-Farber Cancer Institute
Phase 1 Completed
NCT02533258 2025-07-16
Post-Marketing Surveillance Study To Observe INLYTA® Treatment Dosing Pattern, Safety And Effectiveness In Taiwan Real World Routine Practice
Pfizer
Completed
NCT02799095 2025-05-21
A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid Tumors
Mural Oncology, Inc
Phase 1/2 Completed
NCT02899078 2025-05-18
Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney Cancer
University of California, Davis
Phase 1/2 Completed
NCT02440334 2025-05-04
Two and Three Dimensional Contrast-enhanced Ultrasound for Screening of Renal Cell Carcinoma Recurrence Following Cryoablation
Thomas Jefferson University
Phase 2 Completed
NCT04804813 2025-04-11
Survey of Cabozantinib Used To Treat People With Renal Cell Carcinoma
Takeda
Completed
NCT03894618 2025-04-02
SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas
Shattuck Labs, Inc.
Phase 1 Completed
NCT03173560 2025-04-01
Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma
Eisai Inc.
Phase 2 Completed
NCT00720941 2025-03-30
COMPARZ
Novartis
Phase 3 Completed
NCT01147822 2025-03-28
Pazopanib Versus Sunitinib in the Treatment of Asian Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma
Novartis
Phase 2 Completed
NCT05650164 2025-03-28
J-DART2
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Completed
NCT03149822 2025-03-13
Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma
University of Colorado, Denver
Phase 1/2 Completed
NCT01767636 2025-03-03
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer
Mayo Clinic
Phase 2 Completed
NCT01130519 2025-02-21
A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT03190174 2025-02-17
Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers
Sarcoma Oncology Research Center, LLC
Phase 1/2 Completed
NCT03154190 2025-01-24
Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer
Stanford University
Phase NA Completed
NCT02761057 2025-01-13
Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed
National Cancer Institute (NCI)
Phase 2 Completed
NCT04682587 2025-01-03
To Examine the Effects of Axitinib Dose Reduction and Interruption for Adverse Event Management Among Patients Receiving Axitinib in for the Treatment of Advanced Renal Cell Carcinoma
Pfizer
Completed
NCT04068831 2024-12-27
Talazoparib and Avelumab in Participants With Metastatic Renal Cell Carcinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT03138512 2024-12-18
CheckMate 914
Bristol-Myers Squibb
Phase 3 Completed
NCT02926053 2024-11-22
TIL Therapy for Metastatic Renal Cell Carcinoma
Herlev Hospital
Phase 1 Completed
NCT01693822 2024-11-21
A-PREDICT
Institute of Cancer Research, United Kingdom
Phase 2 Completed
NCT03015740 2024-11-19
Sitravatinib and Nivolumab in Treating Patients With Advanced or Metastatic Kidney Cancer
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT02619253 2024-11-18
Phase I/Ib Study of Pembrolizumab With Vorinostat for Patients With Advanced Renal or Urothelial Cell Carcinoma
Indiana University
Phase 1 Completed
NCT02639182 2024-11-18
A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma
Astellas Pharma Inc
Phase 2 Completed
NCT03109015 2024-10-08
ASSET
Duke University
Phase 2 Completed
NCT02667886 2024-10-03
Trial of X4P-001 in Participants With Advanced Renal Cell Carcinoma
X4 Pharmaceuticals
Phase 1/2 Completed
NCT05363072 2024-10-01
A Study to Describe the Kidney Cancer Patient Population Treatment, and Results in the Hospital District of Southwest Finland.
Pfizer
Completed
NCT01210482 2024-09-25
Temsirolimus (Torisel) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)
Pfizer
Completed
NCT03108066 2024-09-24
MK-3795-003
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 2 Completed
NCT04375150 2024-09-19
Master Protocol to Study Treatment Patterns, Medication Adherence, Health and Economic Outcomes and Unmet Needs in RCC
Pfizer
Completed
NCT03334344 2024-08-29
Using Virtual Reality (VR) Models for Preoperative Planning
Ceevra, Inc.
Phase NA Completed
NCT00554515 2024-08-28
SELECT
Beth Israel Deaconess Medical Center
Phase 2 Completed
NCT03693612 2024-08-28
GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors
GlaxoSmithKline
Phase 1/2 Completed